Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAVA-LTE long-term safety extension study of mavacamten in adults with hypertrophic cardiomyopathy
MOH_2019-09-02_007378Phase 3Not yet recruiting
- Sponsor
- MyoKardia
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of mavacamten in hypertrophic cardiomyopathy (HCM), sponsored by MyoKardia. Primary endpoint: Not specified. Planned start Jul 2019; status: not yet recruiting.
02
Drugs
mavacamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on MOH_2019-09-02_007378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-09-02_007378.